The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans

What Was Tested

This randomized controlled trial paper looks at Glucagon.

To investigate the effects of a near-physiological peripheral glucagon-like peptide-1 (GLP-1) infusion, during and after a breakfast of fixed energy content, on resting energy expenditure, substrate oxidation and metabolism and the desire to eat specific types of food in humans.

Visual analogue scales were used throughout the experiment to assess the desire to eat specific types of food and the palatability of the test meals.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

20 healthy, normal weight (body mass index 20.3-25.7 kg/m2) men of 20-31 y of age.

How the Study Was Run

The design is described as randomized, placebo-controlled and crossover.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

A placebo-controlled, randomized, blinded, cross-over study.

Blood was sampled throughout the day for analysis of plasma hormone and substrate concentrations.

What Was Measured

Topics PubMed links to this paper include Basal Metabolism, Body Mass Index, Cholecystokinin, Dietary Carbohydrates, Dietary Fats, Dietary Proteins and Energy Intake.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Glucagon.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2000 (International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity), a journal based in England.

More context: the Glucagon compound page, all human trials.